₹-6.03
(Market cap
₹2,239 Cr
Recently Viewed
Clear AllMarket cap
₹2,239 Cr
Revenue (TTM)
₹1,746 Cr
P/E Ratio
--
P/B Ratio
1.9
Div. Yield
0.8 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹-13 Cr
ROE
7.4 %
ROCE
9.9 %
Industry P/E
47.69
EV/EBITDA
11.9
Debt to Equity
0.6
Book Value
₹96.4
EPS
₹0.9
Face value
2
Shares outstanding
123,300,750
CFO
₹2,263.58 Cr
EBITDA
₹2,708.23 Cr
Net Profit
₹906.08 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Hikal
| -20.2 | 15.7 | -6.9 | -56.6 | -14.5 | -2.7 | 6.6 |
|
BSE Healthcare
| 0.4 | 5.5 | 5.6 | 2.2 | 24.1 | 13.3 | 10.8 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Hikal
| -43.7 | 30.1 | -25.9 | -22.1 | 215.6 | 41.4 | -26.9 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Hikal
|
181.1 | 2,238.5 | 1,745.6 | -13.0 | 4.5 | 0.9 | -- | 1.9 |
| 2,395.0 | 19,609.0 | 1,215.1 | 284.8 | 28.7 | 21.1 | 68.3 | 12.9 | |
| 751.1 | 14,763.9 | 7,266.8 | 627.5 | 11.9 | 12.6 | 23.5 | 2.7 | |
| 360.1 | 13,795.4 | 2,051.5 | 180.5 | 11.6 | 7.7 | 68.4 | 3.6 | |
| 689.5 | 17,075.7 | 5,092.5 | 545.5 | 15.9 | 14.1 | 31.3 | 3.9 | |
| 1,093.2 | 19,566.9 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 12.6 | 2.2 | |
| 1,824.3 | 20,796.8 | 1,419.3 | 20.1 | 8.4 | 0.5 | 1034.6 | 3.6 | |
| 165.5 | 21,992.4 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.8 | |
| 421.2 | 16,971.8 | 3,720.2 | 352.1 | 13.7 | 8.2 | 48.2 | 3.6 | |
| 1,405.2 | 22,831.0 | 3,151.0 | -10.0 | 8.4 | 2.5 | 1037.8 | 4.9 |
No Review & Analysis are available.
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, animal health, biotech, crop protection, and specialty chemicals companies in... India. The company operates through two segments, Pharmaceuticals and Crop Protection. The Pharmaceuticals segment produces active pharmaceutical ingredient (APIs). The Crop Protection segment manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. It also collaborates with other companies and offer solutions in contract research, custom synthesis, and custom manufacturing of intermediates and active ingredients. In addition, the company offers human health products, such as anti-convulsant, anti-emetic, anti-histaminic, anti-depressant, anti-psychotic, anti-lipemic, hemorheologic, anti-diabetic, anti-thrombotic, anti-hypertensive, anti-inflammation, and analgesic; animal health products, such as anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, and NSAID; and specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. It also exports its products. The company operates in the United States, Canada, Europe Union, Japan, Latin America, and internationally. Hikal Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India. Read more
Incorporated
1988
Chairman
Jai Hiremath
Managing Director
Sameer Hiremath
Group
Kalyani
Headquarters
Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsNo News & Announcements are available.
The share price of Hikal Ltd is ₹181.10 (NSE) and ₹181.55 (BSE) as of 24-Apr-2026 IST. Hikal Ltd has given a return of -14.5% in the last 3 years.
Since, TTM earnings of Hikal Ltd is negative, P/E ratio is not available.
The P/B ratio of Hikal Ltd is 1.88 times as on 24-Apr-2026, a 48 discount to its peers’ median range of 3.63 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
54.42
|
3.91
|
|
2024
|
46.99
|
2.75
|
|
2023
|
44.34
|
3.07
|
|
2022
|
30.92
|
4.65
|
|
2021
|
13.29
|
1.90
|
The 52-week high and low of Hikal Ltd are Rs 449.25 and Rs 146.25 as of 24-Apr-2026.
Hikal Ltd has a market capitalisation of ₹ 2,239 Cr as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Hikal Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.